Lupin, Merck Serono join forces targeting emerging markets

Through this partnership, Merck Serono will expand its overall portfolio in core therapeutic areas of Merck Serono’s general medicine & endocrinology franchise in selected countries in Latin America, Asia, Central Eastern Europe, and Africa


(Photo Courtesy:

Lupin will support Merck Serono in the implementation of the company's general medicines portfolio expansion initiative in emerging markets thus addressing local needs for affordable, high‐quality medicines.

The agreement builds on an established working relationship between the two companies, and could add up to 20 new products to the current portfolio.

The first launches are expected in 2016. The partnership covers major markets such as Brazil, Mexico, Indonesia, Philippines alongside several countries in Africa and Central Eastern Europe as well as other countries in emerging markets, focusing on cardiovascular and diabetes diseases.

In Africa, medicines will also be supplied for additional therapeutic areas, reflecting local healthcare needs such as availability of antibiotics.

"The agreement with Lupin is an exciting new approach for Merck Serono to address local health needs in fast‐growing regions with constantly increasing demand for high quality medicines from trusted companies like Merck Serono and Lupin," said Ms Elcin Ergun, head, global commercial, Merck Serono.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email